On June 11, 2025, Summit Therapeutics (SMMT, Financial) has been the subject of new analyst coverage by Leerink Partners. Daina Graybosch, an analyst representing the firm, initiated coverage on SMMT with an “Underperform” rating.
In addition to the rating, Leerink Partners set a price target of $12.00 USD for Summit Therapeutics. There is no prior price target available for comparison, as this is an initiation of coverage by the analyst.
Summit Therapeutics (SMMT, Financial) is listed on the NASDAQ exchange and is currently under scrutiny with this new analyst action. Investors may find this information crucial for reevaluating their positions on SMMT.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Summit Therapeutics Inc (SMMT, Financial) is $33.78 with a high estimate of $44.00 and a low estimate of $5.00. The average target implies an upside of 52.98% from the current price of $22.08. More detailed estimate data can be found on the Summit Therapeutics Inc (SMMT) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Summit Therapeutics Inc’s (SMMT, Financial) average brokerage recommendation is currently 1.7, indicating “Outperform” status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Disclosures
I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
